Date: Published May 2025
Location: Multicenter collaboration led by researchers in Taichung and Tainan, Taiwan.
Study Overview
This systematic review and meta-analysis investigated whether curcumin or turmeric extract acts as an effective adjunct therapy for autoimmune conditions like RA and SLE. Researchers synthesized data from seven randomized controlled trials (RCTs) involving 314 patients to determine if these supplements could significantly lower key inflammatory markers and disease activity.
Key Results
The pooled analysis indicates that curcumin and Curcuma longa extract provided limited and inconsistent benefits for the following primary outcomes:
Disease Activity Score (DAS-28): No significant reduction was found (SMD = -2.34; 95% CI: -5.13 to 0.44).
Erythrocyte Sedimentation Rate (ESR): Supplementation did not result in a statistically significant decrease (SMD = -1.49; 95% CI: -3.71 to 0.72).
C-Reactive Protein (CRP): No significant effect was observed on CRP levels (SMD = -1.65; 95% CI: -3.88 to 0.58).
Statistical Variance: The study noted substantial heterogeneity (I² > 90%) across all results, suggesting high variability between individual trials.
Conclusion: While curcumin is often praised for its anti-inflammatory properties, this meta-analysis suggests its current clinical evidence for RA and SLE is inconclusive. The authors emphasize the need for larger, more rigorous RCTs to determine optimal dosing and efficacy.